In the present study, we demonstrated that CG-806 has a superior anti-leukemia efficacy especially against AML harboring “gatekeeper” F691 mutations or FLT3 WT compared to other FLT3i, without detectable toxicity in normal BM samples. This evidence concerns the gene FLT3 and leukemia.